India CDSCO Medical Device Registration: The Complete Guide

Why India Matters for Medical Device Companies

India is the fourth-largest medical device market in Asia and one of the fastest-growing in the world. The market was valued at approximately USD 14 billion in 2025 and is projected to exceed USD 30 billion by 2030, driven by a population of over 1.4 billion people, expanding healthcare infrastructure, rising chronic disease burden, and substantial government investment through initiatives like Ayushman Bharat and the Production Linked Incentive (PLI) scheme for medical devices.

For foreign manufacturers, India represents a massive opportunity — but one that comes with a regulatory system that has undergone dramatic transformation since 2017. The regulatory landscape is no longer the loosely governed environment it was a decade ago. India has established a comprehensive, risk-based regulatory framework that demands the same kind of serious attention you would give to FDA or EU MDR submissions.

This guide covers everything you need to know: the regulatory authority structure, device classification, registration and import licensing procedures, quality standards, clinical investigation requirements, IVD-specific considerations, pricing controls, post-market obligations, and practical strategies for navigating the Indian market in 2026.

CDSCO: India's Regulatory Authority

The Central Drugs Standard Control Organisation (CDSCO) is the national regulatory body for medical devices in India. It operates under the Ministry of Health and Family Welfare and is headed by the Drugs Controller General of India (DCGI).

CDSCO's medical device regulatory functions include:

• Pre-market evaluation and approval of medical devices and IVDs for manufacture and import
• Licensing of manufacturing facilities and importers
• Clinical trial approval for investigational devices
• Post-market surveillance and vigilance
• Recall management and safety alerts
• Standards development in coordination with the Bureau of Indian Standards (BIS)

CDSCO Structure

CDSCO operates through a headquarters in New Delhi and six zonal offices across the country (Mumbai, Kolkata, Chennai, Hyderabad, Ahmedabad, and Ghaziabad). The zonal offices handle day-to-day licensing activities, while the headquarters manages policy, classification decisions, clinical trial approvals, and import registrations.

The Medical Device Division within CDSCO has been significantly expanded since 2017 to handle the increasing volume of device applications. A dedicated online portal — the Medical Device and Diagnostics Division (MD&D) portal on SUGAM (CDSCO's e-governance platform) — handles electronic submissions.

The SUGAM Portal: India's Online Regulatory Gateway

All medical device regulatory submissions in India are processed through the SUGAM portal (cdscoonline.gov.in), CDSCO's e-governance platform. Understanding how this portal works is essential for any manufacturer or importer.

Portal Registration and Access:

1. Create an account: Navigate to the SUGAM portal and select "Sign Up Here." Choose your applicant type — Indian manufacturer, foreign manufacturer (through authorized Indian agent), importer, testing laboratory, or distributor.
2. Submit organizational credentials: Enter company details including name, address, and contact information. Upload required documents: company PAN card, drug/device license (if existing), and authorization letters.
3. Await verification: CDSCO reviews submitted credentials and activates the account upon verification. Note that hard copies of ID proof, undertaking, and address proof must also be submitted to the CDSCO office — registration is approved only after evaluation of both digital and physical documents.
4. Login: Access the portal using your registered email, password, and captcha verification.

Critical limitation: Foreign manufacturers cannot apply directly through the SUGAM portal. All submissions must be made by the Authorized Indian Agent on behalf of the foreign manufacturer. This is not just a regulatory formality — it means your AIA must have their own SUGAM portal account and be proficient in navigating the system.

Key Forms on the SUGAM Portal:

Form	Purpose
Form MD-1	Application for enrollment by authorized agent or manufacturer
Form MD-2	Import license application (for Class A non-sterile/non-measuring)
Form MD-3	Manufacturing license application
Form MD-4	Loan manufacturing license application
Form MD-5	License renewal application
Form MD-14	Import license application (for all classes requiring import license)
Form MD-15	Import license issued by CDSCO
Form MD-16 / MD-17	Test license applications
Form MD-22	Application to conduct clinical investigation
Form MD-23	Permission granted for clinical investigation
Form MD-40	Import license application (alternate form)
Form CT-04	Clinical trial approval

Application Tracking:

Once an application is submitted, you can monitor its status by logging into the portal, selecting "Track Status," and entering your application number. The system displays one of four statuses: Submitted, Under Review, Approved, or Rejected.

Common Portal Issues and Workarounds:

• File upload failures: The portal has document size limits that can be restrictive for large technical dossiers. Chrome is the recommended browser. Ensure documents are in supported formats (PDF is safest) and within size limits before uploading.
• Login problems: Session timeouts are common. If locked out, use the password recovery function rather than creating a new account.
• Processing delays: Incomplete documentation is the most common cause of delays. Ensure all mandatory fields are completed and all required attachments are uploaded before submission.
• System downtime: The portal occasionally experiences planned and unplanned downtime. The system operates 24/7 in principle, but scheduled maintenance windows do occur. Do not wait until the last day of a deadline to submit.

Digitalized Certificates (April 2025 change): As of April 9, 2025, Market Standing Certificates and Non-Conviction Certificates must be submitted through the updated online portal. Paper-based applications submitted before this date that had not been processed were automatically canceled. This is part of CDSCO's broader push toward fully digital regulatory workflows.

Key Advisory Bodies

• Medical Device Technical Advisory Board (MDTAB): Advises CDSCO on technical matters related to medical device regulation, classification disputes, and policy development.
• Medical Device Committee (MDC): Reviews specific device applications and makes recommendations on registration and licensing decisions.
• Subject Expert Committees (SECs): Specialized panels that evaluate clinical trial applications and complex technical dossiers.

Practical tip: CDSCO's online SUGAM portal has improved significantly since its launch, but the system still has limitations. Application tracking can be inconsistent, and document upload size limits can be restrictive for large technical dossiers. Many regulatory affairs professionals in India maintain parallel offline communication with CDSCO reviewers through their zonal offices. If you are a foreign manufacturer, your Authorized Indian Agent will be your primary interface with CDSCO — choose one with strong working relationships at both headquarters and the relevant zonal office.

Medical Device Rules 2017: The Foundational Framework

Before 2017, medical devices in India were regulated under the Drugs and Cosmetics Act 1940 and its associated rules, which treated devices as a subset of drugs. Only a limited number of device categories — roughly 23 categories including cardiac stents, drug-eluting stents, catheters, orthopedic implants, heart valves, CT scanners, and a few others — were formally notified and regulated. The vast majority of medical devices could enter the Indian market with no regulatory oversight whatsoever.

The Medical Device Rules (MDR) 2017, which came into force on January 1, 2018, changed this fundamentally. For the first time, India established a standalone regulatory framework specifically designed for medical devices, separate from pharmaceutical regulation.

The Fourth Schedule: PMF and DMF Requirements

A critical component of the MDR 2017 that foreign manufacturers must understand is the Fourth Schedule, which defines the two foundational documentation files required for every device submission: the Plant Master File (PMF) and the Device Master File (DMF).

Plant Master File (PMF) — as specified in Appendix 1 of the Fourth Schedule, the PMF provides detailed information about the legal manufacturing site. It must include:

• Manufacturing facility identification: name, address, contact details, and regulatory approvals held
• Facility layout drawings and floor plans showing production areas, clean rooms, and material flow
• Equipment list with maintenance and calibration schedules
• Production process descriptions with raw material specifications
• In-process controls and finished product testing procedures
• Organizational chart (organogram) showing quality, production, and regulatory reporting lines
• ISO 13485 certificates and historical inspection reports
• Environmental monitoring data (for clean room manufacturing)
• Utilities qualification (water systems, HVAC, compressed air)

Device Master File (DMF) — Part IV of the Fourth Schedule specifies the technical documentation required for each device. The DMF must contain:

• Device description and product specifications
• Intended use and indications
• Labeling details (including Indian-specific labeling)
• Design documentation and manufacturing process descriptions
• Risk analysis (ISO 14971)
• Verification and validation data
• Compliance with Essential Principles of Safety and Performance
• Biocompatibility data (IS/ISO 10993) where applicable
• Sterilization validation (where applicable, including parametric release justification for EO, gamma, or steam sterilization)
• Software verification and validation (IEC 62304) where applicable
• Stability data (real-time and accelerated)
• Clinical evidence
• Post-marketing surveillance plan

The PMF and DMF together form the core of every CDSCO submission. They are conceptually similar to the EU Technical File/Design Dossier or the FDA's device submission, but the Indian format has specific structural requirements that differ from both. Your Authorized Indian Agent should guide you on formatting the PMF and DMF according to CDSCO's expectations.

Practical tip: A common mistake by foreign manufacturers is attempting to submit their existing EU Technical File or FDA submission as-is to CDSCO. While the underlying technical content can be reused, it must be reorganized into the PMF/DMF structure defined by the Fourth Schedule. CDSCO reviewers expect documents in their prescribed format, and submissions that do not follow this structure are frequently returned, causing months of delay.

Key Provisions of MDR 2017

The MDR 2017 introduced:

• Risk-based classification into four classes (A, B, C, D), aligned with the Global Harmonization Task Force (GHTF, now IMDRF) framework
• Mandatory registration for all medical devices before manufacture or import
• Quality Management System (QMS) requirements based on ISO 13485
• Clinical investigation rules with ethics committee approval requirements
• Post-market surveillance obligations including adverse event reporting
• Authorized Indian Agent requirements for foreign manufacturers
• Import license requirements with defined validity periods
• Labeling and packaging requirements specific to the Indian market

How MDR 2017 Differs from the Previous Framework

Aspect	Pre-2017 (Drugs & Cosmetics Rules)	MDR 2017
Scope	~23 notified device categories only	All medical devices
Classification	No formal risk classification	4-class risk-based system (A/B/C/D)
Registration	Not required for most devices	Mandatory for all classes
QMS requirement	Informal	ISO 13485 mandatory for Class B, C, D
Clinical evidence	Minimal requirements	Defined clinical investigation rules
Import regulation	License required for notified devices only	Import license required for all devices
Labeling	Drug labeling rules applied	Device-specific labeling requirements
Post-market surveillance	No formal system	Mandatory adverse event reporting

Device Classification: Class A, B, C, and D

India's medical device classification system is based on the GHTF/IMDRF model, using four risk classes. This is conceptually similar to the EU MDR/IVDR system, though the specific classification rules and their application differ in important ways.

Classification Overview

Class	Risk Level	Examples	QMS Requirement	Registration Body
Class A	Low risk	Tongue depressors, examination gloves, bandages, non-powered wheelchairs, reusable surgical instruments	Self-declaration (no third-party QMS audit required, though ISO 13485 is recommended)	CDSCO (registration)
Class B	Low-moderate risk	Hypodermic needles, suction equipment, powered wheelchairs, hearing aids, urinary catheters, ultrasound transducers	ISO 13485 mandatory, Notified Body audit	CDSCO (registration)
Class C	Moderate-high risk	Ventilators, hemodialysis equipment, bone fixation plates, lung ventilators, condoms, infusion pumps	ISO 13485 mandatory, Notified Body audit	CDSCO (registration + import/manufacturing license)
Class D	High risk	Cardiac stents, heart valves, pacemakers, defibrillators, hip prostheses, breast implants	ISO 13485 mandatory, Notified Body audit	CDSCO (registration + import/manufacturing license)

Classification Rules

The MDR 2017 Schedule I contains the classification rules, organized similarly to the GHTF model:

• Rules 1-4: Non-invasive devices (classified based on contact with injured skin, channeling or storing fluids, modifying biological/chemical composition)
• Rules 5-8: Invasive devices (classified based on body orifice vs. surgically invasive, duration of use — transient, short-term, long-term)
• Rules 9-11: Active devices (therapeutic, diagnostic, and those that administer or exchange energy)
• Rules 12-14: Special rules (devices incorporating medicinal substances, devices for contraception or STI prevention, devices for disinfection)
• Rule 15: Devices specifically intended for cleaning, disinfection, or sterilization of medical devices
• Rule 16: Software — standalone software driving or influencing medical device use is classified in its own right

Software Classification

India's approach to software classification under Rule 16 follows the IMDRF framework:

• Software intended to drive or influence the use of a medical device is classified in the same class as the device
• Standalone software intended for diagnosis or therapeutic decisions is classified as Class C or Class D depending on the potential impact of the decision
• Software intended for monitoring (but not driving clinical decisions) may be Class B
• General wellness software with no diagnostic or therapeutic intent is generally not classified as a medical device

Practical tip: Classification disputes are common in India, particularly for combination products, software, and novel device types. CDSCO has the authority to make final classification determinations, and manufacturers can submit a formal classification request. However, this process can take 3-6 months. If your device classification is ambiguous, consider requesting a pre-submission meeting with CDSCO through your Authorized Indian Agent before filing your registration application. Getting classification wrong can result in your application being returned and months of delay.

Registration vs. Import License: Understanding the Two-Track System

One of the most confusing aspects of India's medical device regulation is the distinction between registration and import licensing. These are not the same thing, and foreign manufacturers typically need both.

Registration

Registration is the process by which CDSCO evaluates the safety and performance of a medical device and authorizes it for the Indian market. It applies to all four classes.

• Class A and B devices: Registration is relatively straightforward. The manufacturer submits a registration application with technical documentation, and CDSCO issues a registration certificate.
• Class C and D devices: Registration requires a more detailed technical dossier, including clinical evidence, and involves a thorough review by CDSCO's Medical Device Committee.

Import License

An import license is a separate authorization that allows a specific Indian entity (the importer) to physically bring a registered medical device into India. This is issued at the state level or by CDSCO zonal offices.

Aspect	Registration	Import License
Purpose	Authorizes the device for the Indian market	Authorizes the physical import of a registered device
Issued by	CDSCO headquarters	CDSCO (central licensing authority)
Applicant	Foreign manufacturer (through Authorized Indian Agent)	Indian importer/distributor
Validity	Perpetual for Class A/B; 5 years for Class C/D (renewable)	5 years (renewable)
Pre-requisite	Technical dossier, QMS evidence	Valid device registration
Form	Form MD-14 (registration application)	Form MD-40 (import license application)

The Practical Workflow for Foreign Manufacturers

1. Appoint an Authorized Indian Agent (AIA) — mandatory for all foreign manufacturers
2. Submit a registration application through the AIA via SUGAM portal
3. Obtain the Registration Certificate from CDSCO
4. Your Indian importer/distributor applies for an Import License referencing your Registration Certificate
5. Import License is granted — device can now be commercially imported and distributed

For domestic Indian manufacturers, the equivalent of an import license is a manufacturing license, issued by the State Licensing Authority (SLA) based on a plant inspection. Domestic manufacturers also need the CDSCO registration.

Practical tip: The import license is tied to a specific importer and a specific manufacturer. If you change your Indian distributor, the new distributor needs to apply for a fresh import license. This process can take 3-6 months, creating a gap in your supply chain. Many foreign manufacturers mitigate this risk by having multiple authorized importers in India from the outset.

Registration Dossier Requirements

The documentation requirements vary by device class. The following table summarizes what CDSCO expects in a registration submission.

Documentation by Class

Document	Class A	Class B	Class C	Class D
Registration application (Form MD-14)	Required	Required	Required	Required
Device description and specifications	Required	Required	Required	Required
Intended use / indications for use	Required	Required	Required	Required
Classification justification	Required	Required	Required	Required
QMS certificate (ISO 13485)	Recommended	Required	Required	Required
Design and manufacturing information	Summary	Detailed	Detailed	Detailed
Essential Principles checklist	Required	Required	Required	Required
Risk management file (ISO 14971)	Summary	Required	Required	Required
Biocompatibility data (ISO 10993)	If applicable	If applicable	Required	Required
Electrical safety (IEC 60601-1)	If applicable	If applicable	Required	Required
Software documentation (IEC 62304)	If applicable	If applicable	Required	Required
Sterilization validation	If applicable	If applicable	Required	Required
Clinical evidence	Not required	Summary	Required	Required
Labeling samples (Indian requirements)	Required	Required	Required	Required
Shelf life / stability data	If applicable	Required	Required	Required
Free Sale Certificate (FSC) from country of origin	Required	Required	Required	Required
Certificate of GMP / facility license	Required	Required	Required	Required
Power of Attorney for AIA	Required	Required	Required	Required

Free Sale Certificate Requirements

CDSCO requires a Free Sale Certificate (also called a Certificate of Free Sale or CFS) from the country where the device is manufactured or legally marketed. This certificate must confirm that the device is freely sold in the issuing country and meets the applicable regulatory requirements there. The FSC must be:

• Issued by the regulatory authority of the country of origin (e.g., FDA establishment registration letter plus 510(k) clearance letter, or EU CE certificate)
• Not more than 2 years old at the time of application
• Apostilled or authenticated by the Indian embassy/consulate in the country of origin

Essential Principles of Safety and Performance

India requires manufacturers to demonstrate compliance with the Essential Principles of Safety and Performance laid out in Schedule 2 of the MDR 2017. These are modeled on the GHTF Essential Principles and are conceptually equivalent to the EU MDR's General Safety and Performance Requirements (Annex I). The manufacturer must submit a checklist cross-referencing each applicable Essential Principle to the supporting evidence in the technical dossier.

Bureau of Indian Standards (BIS) Requirements

The Bureau of Indian Standards (BIS) plays an increasingly important role in India's medical device regulatory framework. BIS is India's national standards body, and certain medical devices are subject to mandatory BIS certification under specific Indian Standards (IS) or adopted international standards.

Mandatory BIS Certification

Select categories of medical devices require BIS certification before they can be manufactured in or imported into India. As of 2026, mandatory BIS certification applies to:

• Condoms (IS 3521)
• Cardiac stents (IS 16349 and IS 16391)
• Knee implants (IS 18029 series)
• Surgical gloves (adoption of ISO 10282)
• Absorbable surgical sutures (IS 14222)
• Non-absorbable surgical sutures (IS 15255)
• Intraocular lenses (IS 13364)
• Orthopedic bone plates and screws (multiple IS standards)
• Contact lenses (IS 15923)
• Hearing aids (IS 7480)

The list has been expanding progressively. The Ministry of Commerce, in coordination with CDSCO, periodically adds new device categories to the mandatory BIS certification list through Quality Control Orders (QCOs).

Expanded Standards Landscape (2024-2026)

BIS has dramatically expanded its medical device standards program. Key developments include:

214 High-Priority Device Standards Initiative: Under the National Medical Device Policy 2023, BIS has been tasked with developing Indian Standards for 214 high-priority medical devices by December 2025. The target devices span three broad categories:

• Life-saving equipment (cardiac pacemakers, heart valves, defibrillators)
• Advanced diagnostic equipment (CT scanners, MRI units, ultrasound systems)
• Assistive devices for persons with disabilities (portable ramps, braille displays, hearing aids)

IS 23485 — Medical Devices Quality Management System: BIS has published IS 23485, which covers Quality Management System requirements and Essential Principles of Safety and Performance for medical devices. This is a national adoption that aligns with ISO 13485 while incorporating India-specific requirements for essential principles compliance.

1,700+ BIS Standards Referenced by CDSCO: CDSCO has published a comprehensive reference list of approximately 1,700 standards developed by the BIS Medical Equipment and Hospital Planning Division (MHD). While not all are mandatory, CDSCO may require demonstration of conformity to applicable standards from this list as part of the registration dossier. The list helps manufacturers identify which standards apply to their specific device category.

Quality Control Orders (QCOs) Expansion: As of 2025, BIS has issued 187 QCOs covering over 679 product categories across all sectors. The medical device categories under QCOs are expanding, with new QCOs being implemented on a rolling basis. Notable recent additions include:

• Medical Textiles QCO (October 2024): Mandatory quality standards for medical textiles including surgical gowns, drapes, and related products
• Laser and Aesthetic Devices QCO (March 2026): Mandatory BIS certification for certain laser and intense light aesthetic devices under IS 302 (Part 1): 2024, aligned with IEC 60335-1 electrical safety requirements

Compulsory Registration Scheme (CRS) for Electronic Components: Medical devices that incorporate electronic components (displays, power adapters, batteries, etc.) must also comply with BIS's Compulsory Registration Scheme, administered by the Ministry of Electronics and Information Technology (MeitY). This is a separate requirement from medical device-specific BIS certification. Indian Customs will halt shipments at borders lacking proper CRS certification for electronic components, even if the parent device has its CDSCO registration.

BIS Certification Process

For foreign manufacturers, BIS certification involves:

1. Application submission to BIS with product specifications and test reports
2. Factory inspection by BIS assessors at the manufacturing facility (even if located outside India)
3. Product testing at BIS-recognized laboratories (samples may need to be sent to Indian labs)
4. Grant of BIS license upon satisfactory evaluation
5. Annual surveillance including periodic factory inspections and product testing

The BIS license is valid for one to two years and must be renewed. Foreign manufacturers should note that BIS factory inspections can involve travel to the overseas manufacturing facility by Indian inspectors, which adds time and cost.

Relationship Between BIS and CDSCO

BIS certification and CDSCO registration are separate requirements. A device that requires BIS certification must obtain both — the BIS license for conformity to the relevant Indian Standard, and the CDSCO registration/import license for market authorization. Neither substitutes for the other.

Practical tip: BIS certification timelines have historically been unpredictable, with some applications taking 12-18 months. The government has been working to streamline the process, including allowing recognition of test reports from ILAC-accredited international laboratories for certain product categories. Before starting BIS certification, verify the current list of mandatory standards and recognized testing laboratories. Your Authorized Indian Agent or a BIS consultant can provide updated guidance.

Notified Bodies in India

India's Notified Body system is still maturing compared to the EU or FDA third-party review programs. Under MDR 2017, CDSCO designates Notified Bodies (also called Conformity Assessment Bodies or CABs) to perform QMS audits and, in some cases, technical dossier reviews for Class B, C, and D devices.

Current Notified Body Landscape

As of early 2026, India has designated several Notified Bodies, though the number remains limited:

• Quality Council of India (QCI) — accredits and oversees Notified Bodies
• National Accreditation Board for Certification Bodies (NABCB) — accredits CABs for medical device QMS certification
• Several NABCB-accredited certification bodies operate as Notified Bodies under MDR 2017

For ISO 13485 certification specifically, CDSCO accepts certificates issued by bodies accredited by accreditation bodies that are members of the International Accreditation Forum (IAF) Multilateral Recognition Arrangement (MLA). This means that an ISO 13485 certificate issued by a BSI, TUV, SGS, or similar internationally recognized body is accepted by CDSCO, provided the certificate is current and covers the relevant device scope.

Notified Body Responsibilities

Indian Notified Bodies are responsible for:

• Conducting QMS audits (initial and surveillance) against ISO 13485
• Issuing QMS certificates for Class B, C, and D devices
• Performing product certification where required by specific quality control orders
• Reporting significant non-conformities and concerns to CDSCO

Practical tip: The Indian Notified Body ecosystem is less developed than the EU system. If you already have ISO 13485 certification from an internationally recognized body, that certificate is generally accepted by CDSCO. You do not need to obtain a separate Indian Notified Body certificate for QMS purposes in most cases — but verify this with your Authorized Indian Agent, as requirements have been evolving.

Clinical Investigation Requirements

India's clinical investigation requirements for medical devices have become increasingly rigorous since MDR 2017. The rules are detailed in Chapter V of the MDR 2017 and have been further refined through subsequent amendments and CDSCO guidance documents.

When Clinical Investigation Is Required

Device Class	Clinical Investigation Required?
Class A	Generally not required
Class B	Not typically required; clinical data from literature may suffice
Class C	Clinical evidence required; clinical investigation in India may be required for novel devices or where adequate clinical data is not available
Class D	Clinical investigation in India generally required, unless the device has extensive clinical data from other regulated markets and CDSCO grants a waiver

Clinical Evidence Pathways

CDSCO accepts clinical evidence through several pathways:

1. Clinical investigation conducted in India — the gold standard in CDSCO's view, particularly for higher-risk devices
2. Clinical investigation data from other countries — accepted if the study was conducted under GCP (Good Clinical Practice) and the data is relevant to the Indian patient population
3. Clinical literature review — systematic review of published clinical data for the device or substantially equivalent devices
4. Clinical experience data — post-market clinical data including registry data, real-world evidence
5. Equivalence-based clinical evaluation — demonstrating that the device is equivalent to a device with established clinical evidence (analogous to the EU MDR clinical evaluation approach)

Clinical Investigation Approval Process

For clinical investigations conducted in India:

1. Ethics Committee approval — from an Ethics Committee registered with the Clinical Trial Registry of India (CTRI) and recognized under the New Drugs and Clinical Trial Rules 2019 (which apply to device clinical investigations by reference)
2. CDSCO approval — application submitted to CDSCO's Medical Device Division with the clinical investigation protocol, investigator brochure, informed consent documents, and Ethics Committee approval
3. Clinical Trial Registry — all clinical investigations must be registered on CTRI before enrolling the first subject
4. CDSCO review timeline — CDSCO aims to review clinical investigation applications within 90 days, though in practice it can take longer
5. Investigation conduct — must follow Indian GCP guidelines, with regular reporting to CDSCO and the Ethics Committee
6. Serious Adverse Event (SAE) reporting — within 14 days to CDSCO, Ethics Committee, and sponsor

Clinical Investigation Forms

Two specific forms govern the clinical investigation approval process:

Form MD-22 is the application submitted to the Central Licensing Authority (CDSCO) requesting permission to conduct a clinical investigation. It must include:

• Applicant details (name, legal constitution — proprietorship, partnership, company, society, or trust)
• Sponsor contact details and clinical investigation site addresses
• Device information (generic name, intended use, device class)
• Ethics Committee details for each site
• Clinical Investigation Plan number and date
• Fee payment documentation
• Undertaking of compliance with the Drugs and Cosmetics Act 1940 and MDR 2017
• All supporting documents specified in the Seventh Schedule of MDR 2017

Form MD-23 is the approval document issued by CDSCO granting permission to proceed. It specifies the approved investigation sites, principal investigator names, investigational device details, and conditions of approval. It is digitally signed by the Central Licensing Authority.

Critical enrollment timeline: The first participant must be enrolled within one year from the date permission is granted in Form MD-23. If recruitment is not completed within this timeframe, prior approval from CDSCO is required to continue enrollment.

Compensation Requirements

India has strict requirements for compensation of clinical investigation subjects who suffer injury. Under the New Drugs and Clinical Trial Rules 2019 (applied to devices by reference), sponsors are required to provide compensation (including medical management) to subjects who suffer injury as a result of the clinical investigation. This is a mandatory obligation — not discretionary — and applies regardless of whether the injury was foreseeable.

The Compensation Formula (Seventh Schedule):

India prescribes a specific mathematical formula for calculating compensation, which is unusual among global regulatory systems and significantly more prescriptive than the US or EU approaches.

For death during clinical investigation:

Compensation = (B x F x R) / 99.37

Where:

• B = Base amount of Rs. 8 lakhs (approximately USD 9,600)
• F = Age-based factor from Annexure 1 of the Seventh Schedule, ranging from 228.54 (for subjects aged 16 or younger) to 99.37 (for subjects aged 65 or older). Younger subjects receive higher compensation.
• R = Risk factor on a scale of 0.5 to 4.0, based on the severity of the underlying disease:
  • 4.0 = Terminally ill patients (life expectancy of 6 months or less)
  • 3.0 = High-risk patients (life expectancy of 6-24 months)
  • 2.0 = Moderate-risk patients
  • 1.0 = Mild-risk patients
  • 0.5 = Healthy volunteers

Exception: When expected mortality exceeds 90% within 30 days, a fixed amount of Rs. 2 lakhs (approximately USD 2,400) applies.

For permanent disability:

Compensation = (C x D x 90) / (100 x 100)

Where C = the death compensation amount (calculated above) and D = disability percentage. The total cannot exceed the death compensation amount.

For hospitalization due to a Serious Adverse Event (SAE):

Compensation = 2 x W x N

Where W = minimum daily wage of an unskilled worker in Delhi (updated annually) and N = number of hospitalization days.

For congenital anomaly or birth defect: Half the base amount as a lump sum, plus ongoing medical management for the affected child.

All financial compensation is in addition to expenses incurred on medical management of the subject. The Central Licensing Authority makes the final determination on compensation quantum after considering the recommendations of an expert committee.

Practical tip: Clinical investigations in India are operationally complex. The Ethics Committee landscape is fragmented, with varying quality across institutions. Site selection is critical — choose sites with established clinical investigation infrastructure and investigators experienced with device trials. Many foreign sponsors partner with Indian Contract Research Organizations (CROs) that specialize in medical device trials. Budget 6-12 months for regulatory and ethics approvals before you can begin enrollment.

MDR 2017 Amendments and Regulatory Evolution

The MDR 2017 has been amended multiple times since its introduction, reflecting the government's iterative approach to building the regulatory framework. Key amendments and developments include:

Major Amendments Timeline

Year	Amendment / Development	Key Changes
2018	MDR 2017 comes into force	Baseline framework established
2020	Notification of additional device categories	Scope expanded to cover all medical devices in phases; devices previously unregulated brought under MDR
2020-2021	COVID-19 emergency provisions	Accelerated approval pathways for ventilators, PPE, diagnostic kits, pulse oximeters; temporary manufacturing licenses
2022	Amendment to classification rules	Refinements to software classification; clarification of IVD classification rules
2023	Risk-based import licensing reform	Streamlined import license process for Class A/B devices; reduced documentation requirements for lower-risk categories
2024	Digital health regulatory framework	Draft guidance on regulation of AI/ML-based medical devices; Software as a Medical Device (SaMD) classification clarifications
2024	Single-window clearance initiative	Integration of CDSCO, BIS, and customs clearance into unified electronic platform (phased rollout)
2024	Risk-based quality monitoring for imports (September 2024)	Stratified surveillance system for imported devices; high-priority products (diagnostic kits) face stricter scrutiny; three-step inspection: visual examination, field testing, complete laboratory testing
2025	MDR 2017 comprehensive amendment	Updated clinical investigation rules; alignment with IMDRF guidance on MDSAP; revised post-market surveillance requirements; introduction of Unique Device Identification (UDI) system for Class C and D devices
2025	Cardiovascular and neurological device reclassification (April 2025)	553 devices reclassified: 351 cardiovascular and 202 neurological products distributed across Class D (221), Class B (153), Class C (151), and Class A (28)
2025	Digitalized certificates (April 2025)	Market Standing Certificates and Non-Conviction Certificates must be submitted through online portals; paper-based applications canceled
2025-2026	UDI implementation	Phased rollout of India's UDI system, starting with Class D devices (mandatory from April 2025) and Class C devices (mandatory from October 2025)

FAQ Addenda: CDSCO's Evolving Guidance

CDSCO has adopted a practice of issuing supplementary FAQ addenda to clarify implementation of the MDR 2017. These addenda are critical reading for regulatory affairs professionals because they often resolve ambiguities not addressed in the rules themselves.

Addendum	Date	Key Topics Covered
First Addendum	April 3, 2024	Regulatory procedures, approvals, biocompatibility requirements, site-specific applications, post-market surveillance, and compliance requirements
Second Addendum	July 9, 2024	Labeling rules, re-import approvals, SaMD and SiMD (Software in a Medical Device) classification, post-approval change procedures, and general licensing clarifications
Third Addendum	November 2025	Import license requirements for raw materials and components, post-approval change procedures, authorized agent documentation, and import permissions through notified ports

These addenda carry practical regulatory weight even though they are not formal gazette notifications. CDSCO reviewers reference them when evaluating applications, and your AIA should be tracking these updates and advising you on their implications for your submissions.

Risk-Based Quality Surveillance for Imports (September 2024)

In September 2024, CDSCO introduced a new stratified surveillance strategy for monitoring the quality of imported medical devices. This represents a shift from uniform inspection to risk-proportionate scrutiny:

• High-priority products (diagnostic kits, certain implants): Subject to stricter and more frequent quality testing
• Vaccines and biologics: Entire shipments undergo full inspection
• Standard medical devices: Randomly sampled through a three-step process — visual examination, field testing under actual use conditions, and complete laboratory testing as warranted

This system means that importers of high-risk devices should expect more frequent quality checks at the point of customs clearance. Factor potential sampling delays into your import logistics planning, particularly for time-sensitive products.

Reclassification of Cardiovascular and Neurological Devices (2025)

In April 2025, CDSCO issued a major draft reclassification affecting 553 medical devices across cardiovascular and neurological categories. This is one of the largest single reclassification actions taken under MDR 2017:

• 351 cardiovascular devices reclassified, including cardiac catheters, vascular grafts, pacemaker leads, and cardiac monitoring systems
• 202 neurological devices reclassified, including neurostimulators, shunt systems, and neurological diagnostic instruments
• Distribution: Class D (221 devices), Class B (153), Class C (151), Class A (28)

The reclassification aligns with IMDRF guidelines and First Schedule (Part 1) of MDR 2017. If your device falls into either category, verify your current classification against the updated lists — a reclassification to a higher class triggers additional documentation requirements, potentially including clinical evidence and Notified Body audit.

India's Unique Device Identification (UDI) System

India launched its UDI system in 2025, modeled on the US FDA UDI framework and aligned with IMDRF UDI guidance. Key features:

• UDI consists of a Device Identifier (UDI-DI) and a Production Identifier (UDI-PI)
• CDSCO has recognized GS1 India as the issuing agency for UDI-DIs
• The UDI database is integrated into the SUGAM portal
• Class D devices: UDI mandatory from April 2025
• Class C devices: UDI mandatory from October 2025
• Class B devices: UDI mandatory from April 2026
• Class A devices: Timeline to be announced

Recent Regulatory Reforms (2024-2026)

Several significant reforms have been introduced or proposed in the 2024-2026 period:

Rationalization of regulatory approvals: CDSCO has introduced a risk-proportionate review system where Class A and B device registrations receive expedited review (target: 30-60 days) while Class C and D devices undergo full technical review (target: 90-180 days).

Mutual recognition of QMS audits: India has been exploring recognition of MDSAP (Medical Device Single Audit Program) audit reports as evidence of QMS compliance, which would eliminate the need for separate QMS audits for manufacturers already participating in MDSAP. As of early 2026, this is accepted on a case-by-case basis but not yet formally codified.

Digital health framework: CDSCO published draft guidance in 2024 on the regulation of AI/ML-based Software as a Medical Device (SaMD). The framework classifies AI/ML-based SaMD using a risk matrix considering the seriousness of the condition and the significance of the software's contribution to the clinical decision. Locked algorithms follow the standard classification process, while adaptive (continuously learning) algorithms are subject to additional requirements including a Predetermined Change Control Plan — conceptually similar to the FDA's approach.

Harmonization efforts: India has been actively participating in IMDRF and engaging bilaterally with the US FDA, EU Commission, and other regulatory authorities on convergence initiatives. A mutual recognition agreement framework with the US FDA for QMS inspections has been under discussion.

Authorized Indian Agent Requirements

Every foreign manufacturer seeking to register medical devices in India must appoint an Authorized Indian Agent (AIA). This is not optional — it is a legal requirement under MDR 2017.

Who Can Be an AIA?

An Authorized Indian Agent must be:

• A legal entity registered in India (company, LLP, or partnership firm)
• Located in India with a physical business address
• Authorized by the foreign manufacturer through a Power of Attorney or formal authorization letter
• Capable of acting as the single point of contact between the foreign manufacturer and CDSCO

AIA Responsibilities

The AIA's obligations include:

• Submitting regulatory applications on behalf of the foreign manufacturer to CDSCO
• Maintaining regulatory files and correspondence with CDSCO
• Facilitating post-market surveillance including adverse event reporting
• Ensuring compliance with Indian labeling and packaging requirements
• Coordinating inspections and responding to CDSCO queries
• Maintaining product recall capability in coordination with the foreign manufacturer
• Keeping CDSCO informed of any changes to the device, manufacturing site, or QMS certification

AIA vs. Importer

The AIA and the importer can be the same entity, but they do not have to be. Many foreign manufacturers appoint their Indian distributor as both AIA and importer. Others appoint a specialized regulatory consultancy as the AIA and keep the import license with a separate distribution partner.

Role	AIA	Importer
Primary function	Regulatory representative	Commercial import
Relationship	With foreign manufacturer and CDSCO	With CDSCO (for import license) and customs
Mandatory?	Yes, for all foreign manufacturers	Yes, for physical import of devices
Can be same entity?	Yes	Yes
Regulatory filings	Submits registration applications	Applies for import license
Post-market obligations	Adverse event reporting coordination	Import documentation, customs compliance

Practical tip: Choosing the right AIA is one of the most consequential decisions you will make when entering the Indian market. A good AIA brings regulatory expertise, established relationships with CDSCO reviewers, and the ability to navigate the system's informal dimensions — which matter more than many foreign manufacturers realize. A poor AIA can result in applications sitting in queues for months without follow-up. Due diligence should include: track record with CDSCO (ask for examples of successful registrations in your device category), responsiveness, understanding of your specific device type, and references from other foreign manufacturers they represent. Avoid AIAs who represent competing products, as conflicts of interest can create problems.

Make in India and the PLI Scheme

India's industrial policy has significant implications for the medical device sector. Two government initiatives are particularly relevant: the Make in India program and the Production Linked Incentive (PLI) scheme.

Make in India

Launched in 2014, Make in India is a national initiative to encourage manufacturing in India across multiple sectors, including medical devices. Its relevance to device manufacturers includes:

• Import substitution focus: The government actively encourages domestic manufacturing of medical devices that India currently imports. Customs duty structures are periodically adjusted to make imported devices more expensive relative to domestically manufactured alternatives.
• Customs duty on imported devices: As of 2026, basic customs duty on imported medical devices ranges from 0% (for certain life-saving devices) to 15% (for devices where domestic alternatives are available). Health cess of 5% on customs duty also applies.
• Public procurement preferences: Government hospitals and procurement agencies (such as the Central Government Health Scheme and various state health missions) increasingly give preference to domestically manufactured devices in their tenders. The Public Procurement (Preference to Make in India) Order applies to medical devices and can provide 20% price preference for locally manufactured products.
• Special Economic Zones (SEZs) and Medical Device Parks: The government has established dedicated Medical Device Parks in states including Andhra Pradesh, Himachal Pradesh, Madhya Pradesh, Tamil Nadu, Uttar Pradesh, and Kerala. These parks offer subsidized land, shared infrastructure (clean rooms, testing labs, sterilization facilities), and tax incentives to attract device manufacturers.

Production Linked Incentive (PLI) Scheme for Medical Devices

The PLI scheme for medical devices, launched in 2020 and expanded through 2025, provides financial incentives to manufacturers who establish or expand production capacity in India.

Key features of the PLI scheme:

• Total financial outlay: Rs. 3,420 crore (approximately USD 410 million) — this is the government's total committed budget for the scheme
• Production tenure: FY 2022-23 through FY 2026-27 (five-year incentive period), with the overall scheme running from FY 2020-21 through FY 2027-28
• Incentive structure: 5% of incremental sales (over base year) for a period of five years
• Minimum investment threshold: INR 10 crore (approximately USD 1.2 million) for SMEs; INR 25 crore (approximately USD 3 million) for others
• Target product categories (four segments): The scheme specifically targets four device segments where India has high import dependence:
  1. Cancer care and radiotherapy devices (linear accelerators, brachytherapy systems, cobalt therapy units)
  2. Radiology and imaging devices — both ionizing and non-ionizing radiation products, including nuclear imaging equipment (CT, MRI, X-ray, mammography, C-arms, ultrasound, PET-CT)
  3. Anesthetics, cardio-respiratory devices, catheters, and renal care devices (ventilators, dialysis machines, anesthesia workstations)
  4. All implants, including implantable electronic devices (orthopedic, cardiovascular, ophthalmic, cochlear, neurostimulators)

Program results (as of 2025): The PLI scheme has delivered tangible outcomes:

• 19 greenfield manufacturing projects commissioned across India
• Production started for 44 medical device products, including high-end devices such as linear accelerators, MRI machines, CT scanners, mammography systems, C-arms, and ultrasound machines — devices that were previously entirely imported
• The scheme is explicitly described as moving toward "Atmanirbhar Bharat" (self-reliant India) in the medical device sector

Eligibility: Both domestic companies and foreign companies manufacturing in India are eligible. The PLI scheme explicitly welcomes foreign direct investment (FDI) in medical device manufacturing. 100% FDI is permitted under the automatic route for medical device manufacturing.

Application and implementation: The scheme is administered by IFCI Ltd. (formerly Industrial Finance Corporation of India) on behalf of the Department of Pharmaceuticals. Applications are submitted through the dedicated PLI Medical Devices portal (plimedicaldevices.ifciltd.com). Selected applicants must achieve minimum investment thresholds and demonstrate incremental sales growth to receive annual incentive disbursements.

Implications for Foreign Manufacturers

The Make in India push creates both incentives and pressures for foreign manufacturers:

Incentives:

• PLI subsidies can significantly improve manufacturing economics
• Medical Device Parks reduce infrastructure costs
• Growing domestic market justifies local production investment
• Favorable FDI policy makes investment straightforward

Pressures:

• Rising customs duties on imported devices
• Public procurement preferences for domestic products
• Political expectation that major international manufacturers will establish local operations
• Technology transfer requirements in some government tenders

Practical tip: You do not need to manufacture in India to sell in India — imported devices remain a viable and common market entry strategy. But the economics are tilting toward local manufacturing for high-volume products. If your device has significant volume potential in India, run a manufacturing economics analysis comparing import vs. local production, factoring in customs duties, PLI incentives, public procurement advantages, and the Medical Device Park benefits. Many major multinational device companies (Medtronic, Abbott, Johnson & Johnson MedTech, Siemens Healthineers, BD) have established or expanded manufacturing in India over the past five years.

Registration Timeline and Fees

Understanding realistic timelines and current fee structures is essential for planning your India market entry.

Typical Registration Timelines

Process Step	Class A	Class B	Class C	Class D
Preparation of registration dossier	1-2 months	2-3 months	3-6 months	4-8 months
CDSCO registration review	1-2 months	2-4 months	4-8 months	6-12 months
Registration certificate issued	—	—	—	—
Import license application and review	1-3 months	1-3 months	2-4 months	2-4 months
Total estimated timeline	3-6 months	5-10 months	9-18 months	12-24 months

These are general estimates. Actual timelines depend on the completeness of the application, CDSCO reviewer workload, the novelty of the device, any queries raised during review, and the effectiveness of your Authorized Indian Agent.

Fee Structure

CDSCO fees are prescribed by the government and have two components: the INR-denominated regulatory application fees (which are very low) and the USD-denominated registration and inspection fees (which were introduced for foreign manufacturers and are higher but still modest by global standards).

INR-Denominated Application Fees:

Fee Type	Amount (INR)	Approximate USD
Registration application — Class A	INR 2,500	~$30
Registration application — Class B	INR 5,000	~$60
Registration application — Class C	INR 10,000	~$120
Registration application — Class D	INR 15,000	~$180
Import license application	INR 5,000 per device per manufacturer	~$60
Import license renewal (5-year)	INR 3,000 per device	~$36
Clinical investigation application	INR 50,000	~$600
Retention fee (annual, for import license)	INR 1,000 - 5,000 per device	~$12-60

USD-Denominated Fees for Foreign Manufacturers:

In addition to the INR application fees, foreign manufacturers face USD-denominated fees for registration and inspection:

Fee Type	Amount (USD equivalent)
Manufacturing premises registration	USD 1,500
Single device registration	USD 1,000 per device
Each additional device under same application	USD 1,000 per device
Import license application (Form MD-40)	USD 1,500
Manufacturing premises inspection (if required)	USD 5,000

Payment methods: Fees can be paid through a TR-6 Challan at designated branches of Bank of Baroda (for INR fees) or via Electronic Clearance System (ECS) for payments made from abroad (for USD fees). Your Authorized Indian Agent typically handles fee payments on your behalf.

Registration validity: Import licenses and registration certificates are typically valid for three to five years and must be renewed before expiry. Allow adequate lead time for renewal applications — submitting renewal applications at least 6 months before expiry is strongly recommended.

The government fees are low, but the total cost of India registration is significantly higher when you account for:

• Authorized Indian Agent fees (typically USD 5,000 - 25,000 depending on device class and AIA)
• Dossier preparation (in-house or consultant, USD 5,000 - 30,000)
• BIS certification costs if applicable (USD 5,000 - 20,000 including testing)
• Clinical investigation costs if required (highly variable, USD 50,000 - 500,000+)
• ISO 13485 certification if not already held

Total Estimated Cost for Foreign Manufacturer

Cost Component	Class A/B	Class C	Class D
CDSCO fees	$60 - $100	$120 - $200	$180 - $250
AIA fees	$3,000 - $8,000	$8,000 - $15,000	$12,000 - $25,000
Dossier preparation	$3,000 - $8,000	$8,000 - $20,000	$15,000 - $30,000
BIS certification (if applicable)	$5,000 - $10,000	$5,000 - $15,000	$10,000 - $20,000
Clinical investigation (if required)	N/A	$50,000 - $200,000	$100,000 - $500,000+
Total (excluding clinical)	$11,000 - $26,000	$21,000 - $50,000	$37,000 - $75,000

Practical tip: CDSCO government fees are not the issue — they are almost negligible. The real costs are AIA fees, dossier preparation, and especially clinical investigations. For Class C and D devices, clinical investigation requirements are the single biggest cost and timeline variable. Clarify with CDSCO early — through your AIA — whether a clinical investigation in India will be required, or whether international clinical data will be accepted. This decision alone can swing your budget by hundreds of thousands of dollars and your timeline by a year or more.

IVD Registration Specifics

In vitro diagnostic devices (IVDs) are regulated under the same MDR 2017 framework as other medical devices, but with some IVD-specific provisions and practical differences.

IVD Classification

IVDs in India are classified using the same A/B/C/D system, but with IVD-specific classification rules:

IVD Class	Risk Level	Examples
Class A	Low risk	Specimen containers, wash solutions, general laboratory instruments without measurement function
Class B	Low-moderate risk	Clinical chemistry analyzers, routine hematology instruments, urine test strips, pregnancy self-test kits
Class C	Moderate-high risk	Blood glucose meters, HbA1c tests, companion diagnostics, blood grouping reagents, tumor marker assays, genetic testing kits
Class D	High risk	HIV test kits, Hepatitis B/C test kits, blood screening for transfusion, SARS-CoV-2 diagnostic tests

IVD-Specific Registration Requirements

• Analytical performance data: Sensitivity, specificity, precision (repeatability and reproducibility), linearity, measuring range, limit of detection, limit of quantification
• Clinical performance data: Clinical sensitivity, clinical specificity, positive/negative predictive values based on clinical studies
• Reference materials/standards: Traceability to international reference materials where available
• Stability data: Real-time stability, accelerated stability, in-use stability, shipping stability
• Indian population validation: For certain IVDs, particularly infectious disease diagnostics, CDSCO may require performance validation on Indian population samples. This is because disease prevalence, genetic variants, and strain diversity can affect diagnostic performance.

IVD Import License Considerations

IVD reagents and test kits that have limited shelf life face additional practical challenges with India's import license and customs clearance timelines. Delays at customs can erode shelf life, particularly for temperature-sensitive reagents.

Practical tip: For IVDs intended for infectious disease diagnosis, expect CDSCO to require Indian population validation data, particularly for Class C and D IVDs. This means you will need to work with Indian clinical sites to test your IVD on locally collected samples. Plan for this early — sourcing appropriate clinical samples in India, establishing site agreements, and obtaining Ethics Committee approvals all take time. For IVDs that India considers critical for public health (HIV, TB, hepatitis, malaria), CDSCO review can sometimes be faster than standard timelines because of government priority programs.

Post-Market Requirements

India's post-market surveillance framework has been strengthened significantly since 2017. Manufacturers and importers have defined obligations for monitoring device performance after market entry.

Adverse Event Reporting

Manufacturers and importers must report adverse events to CDSCO:

Event Type	Reporting Timeline
Death or serious injury caused or potentially caused by the device	Within 10 days of becoming aware
Near-miss events that could have led to death or serious injury	Within 30 days
Malfunction that could lead to death or serious injury if it recurs	Within 30 days
Trend reporting (increased frequency of non-serious events)	Quarterly

Reports are submitted through the CDSCO SUGAM portal using the prescribed Medical Device Adverse Event Reporting form.

Field Safety Corrective Actions (FSCA)

When a manufacturer initiates a recall or field safety corrective action anywhere in the world for a device registered in India, CDSCO must be notified. India does not automatically follow other regulatory authorities' recall decisions — CDSCO makes its own determination — but the manufacturer is required to inform CDSCO of any global FSCA and provide a risk assessment specific to the Indian market.

Post-Market Surveillance Plan

Class C and D device manufacturers are required to maintain a post-market surveillance plan that includes:

• Systematic collection and analysis of complaints and adverse events
• Periodic review of scientific literature relevant to the device
• Analysis of data from similar devices on the market
• Trending analysis of adverse events and complaints
• Summary reports submitted to CDSCO at defined intervals

Periodic Safety Update Reports (PSUR)

For Class C and D devices, CDSCO requires periodic safety update reports:

• Class C: PSUR every 2 years
• Class D: PSUR annually

The PSUR must include a summary of all adverse events, complaints, field safety corrective actions, and an updated benefit-risk assessment.

Materiovigilance Programme of India (MvPI)

The Materiovigilance Programme of India (MvPI) is the national program for monitoring medical device adverse events, operated by the Indian Pharmacopoeia Commission (IPC) under the oversight of the Drugs Controller General of India (DCGI). Understanding MvPI is critical because it is the operational arm of India's post-market surveillance system.

November 2024 Updates: The DCGI introduced significant revisions to MvPI, including a revamped adverse event reporting form. The updated form captures:

• Expanded product information: risk classification, importer/manufacturer license number, date of manufacture
• More detailed incident description fields
• Suggested corrective measures from the reporter
• Confidentiality protections for patient and reporter identities

March 2025 Expert Committee: The Health Ministry established a new expert committee under MvPI consisting of specialists in cardiology, neurology, radiology, and other disciplines. This committee verifies reported incidents and recommends safety measures, significantly strengthening the credibility and responsiveness of India's post-market surveillance for high-impact devices.

Current reporting mechanism: India currently uses email-based reporting through MvPI and manual adverse event reporting forms available on the IPC website. While less sophisticated than the FDA's MedWatch or the EU's EUDAMED vigilance system, MvPI is improving rapidly. Updated forms and guidance documents are available at ipc.gov.in.

Practical implication for manufacturers: The strengthened MvPI means that adverse event reports in India are increasingly likely to trigger follow-up from CDSCO. Manufacturers and importers should ensure they have robust processes for receiving, investigating, and responding to Indian adverse event reports within the prescribed timelines. Your AIA plays a key role in this — ensure your AIA has a clear process for MvPI reporting and CDSCO communication on vigilance matters.

Uniform Code for Marketing Practices in Medical Devices (UCMPMD)

In September 2024, the Department of Pharmaceuticals launched the Uniform Code for Marketing Practices in Medical Devices (UCMPMD) — India's first dedicated code for regulating the promotion and marketing of medical devices. This is a significant development that foreign manufacturers must incorporate into their India commercial operations.

Key Provisions

Prohibition on pre-approval promotion: A medical device must not be promoted before receiving product approval from the relevant regulatory authority. All promotional claims must align with the terms outlined in the documents submitted for product registration or licensing.

Ethical standards for representatives: Medical representatives — including sales staff, marketing personnel, clinical specialists, and third-party contracted personnel — must maintain high ethical standards. The code prohibits using inducements or subterfuge to gain access to healthcare professionals.

Prohibited practices with healthcare professionals (HCPs):

• Extravagant hospitality at conferences
• Paid vacations or travel unrelated to legitimate educational purposes
• Cash payments or monetary incentives to prescribe or recommend specific devices
• Unrestricted product sampling without documentation
• Gifts exceeding nominal value

Accurate and balanced promotion: Product information shared with HCPs must be current, accurate, and balanced, ensuring it does not mislead either directly or indirectly. Off-label promotion is prohibited.

Compliance and Enforcement

Annual self-declaration requirement (starting 2025): Before the end of June each year, the executive head of every medical device company operating in India must submit a self-declaration confirming that the business was conducted in compliance with UCMPMD in the previous financial year (April-March) and will continue to comply in the coming year.

Expenditure disclosure: Along with the self-declaration, companies must disclose expenditure incurred in the previous financial year on:

• Sponsorship of third-party and internal HCP educational and training programs
• Distribution of free evaluation samples to HCPs

Industry Ethics Committees: All medical device industry associations are required to constitute an Ethics Committee for Marketing Practices in Medical Devices, chaired by the association CEO with 3-5 members, to handle complaints and enforce the code.

Penalties for violations: If a UCMPMD violation is confirmed, the Ethics Committee or Apex Committee may:

• Suspend or expel the company from the industry association
• Issue a public reprimand with details of the violation
• Require the company to issue a corrective statement
• Demand recovery of money or items provided in violation of the code
• Forward recommendations to government agencies for disciplinary, penal, or remedial action

Practical tip: While the UCMPMD is currently structured as a voluntary code with self-regulatory enforcement rather than statutory penalties, the trajectory in India is toward making such codes mandatory. Foreign manufacturers should treat UCMPMD compliance as a requirement, not an option. Non-compliance creates reputational risk and could trigger regulatory attention, particularly given the government's increasing scrutiny of medical device marketing practices. Ensure your India commercial team and distributors are trained on UCMPMD requirements, and incorporate the annual self-declaration and expenditure disclosure into your compliance calendar.

Pricing Regulations: NPPA and Price Controls

One aspect of the Indian medical device market that catches many foreign manufacturers off guard is pricing regulation. India has an active price control mechanism for medical devices, administered by the National Pharmaceutical Pricing Authority (NPPA).

NPPA Background

The NPPA was originally established to regulate pharmaceutical prices, but its mandate was extended to medical devices in 2017 when cardiac stents were brought under price control. Since then, the scope of price-controlled devices has expanded.

Devices Under Price Control

As of 2026, the following device categories are subject to NPPA price caps:

Device Category	Year Brought Under Price Control	Impact
Coronary stents (bare metal and drug-eluting)	2017	Price caps reduced stent prices by 65-85%
Knee implants	2017	Price caps reduced knee implant prices by 50-70%
Hip implants	2024	Price caps established based on trade margin rationalization
Intraocular lenses	2020	Price caps based on trade margin rationalization
Oxygen concentrators	2021 (COVID-era, extended)	54% reduction in MRP; trade margin capped at 70% at first point of sale
Pulse oximeters	2021 (COVID-era, extended)	Trade margin rationalization applied
Blood pressure monitors	2021 (COVID-era, extended)	Trade margin rationalization applied
Digital thermometers	2021 (COVID-era, extended)	Trade margin rationalization applied
Glucometers	2021 (COVID-era, extended)	Trade margin rationalization applied
Nebulizers	2021 (COVID-era, extended)	Trade margin rationalization applied
Hormone-releasing IUDs	2023	Ceiling price of Rs. 3,659.68 per IUD (52mg levonorgestrel)
Heart valves	Under consideration	Potential future price control
Cochlear implants	Under consideration	Potential future price control

Specific Ceiling Prices (Current as of April 2025)

Understanding the actual price caps is essential for business planning. NPPA adjusts ceiling prices annually based on the Wholesale Price Index (WPI):

Coronary Stents (effective April 2025, per NPPA notification S.O. 1473(E) dated March 27, 2025):

• Bare Metal Stents: Rs. 10,692.69 per unit (approximately USD 128)
• Drug-Eluting Stents (DES), including Bioresorbable Vascular Scaffolds (BVS) and biodegradable stents: Rs. 38,933.14 per unit (approximately USD 467)
• The April 2025 revision reflects a 1.74% WPI increase over the previous year's ceiling prices of Rs. 10,509.20 (BMS) and Rs. 38,265.07 (DES)

Knee Implants: NPPA has repeatedly extended the ceiling price applicability for orthopedic knee implants, most recently through notification S.O. 3869(E) dated September 10, 2024, extending ceiling prices until November 15, 2025. Further extensions are expected as the government continues its review of long-term pricing policy for implants.

Oxygen Concentrators: Following the COVID-19 crisis, NPPA capped prices of 5-liter oxygen concentrators at Rs. 40,000-60,000 (reduced from market prices of Rs. 77,000-88,000), representing a 54% reduction.

These price points are drastically lower than global prices for the same devices. A drug-eluting stent that sells for USD 2,000-3,000 in the US is capped at approximately USD 467 in India. Manufacturers must build their India business case around these ceiling prices, not their global price list.

Trade Margin Rationalization

Rather than setting absolute price caps for all devices, NPPA has increasingly used a Trade Margin Rationalization (TMR) approach. Under TMR, NPPA caps the trade margin (the difference between the price to the first point of sale in India and the price to the patient) rather than the absolute price. This approach allows market-based pricing at the manufacturer level while controlling distribution chain markups that historically added 200-500% to the cost of implants.

How TMR works in practice: For devices under TMR (such as oxygen concentrators), NPPA caps the trade margin at a specified percentage — for example, 70% at the first point of sale to distributors. The manufacturer's ex-factory price is not directly controlled, but the maximum retail price is derived from the ex-factory price plus the capped trade margin. This means manufacturers retain some pricing flexibility, but the end-user price is constrained.

Expanding scope: Two government committees — one within the Ministry of Health and Family Welfare, another within NPPA — are simultaneously developing a comprehensive price control policy for the medical device sector. The health ministry committee is identifying additional devices to classify as "essential" and bring under direct price control, while the NPPA committee is developing a pricing formula applicable to both scheduled and non-scheduled medical devices. The clear trajectory is toward broader price regulation, not less.

Impact on Market Entry Strategy

Price controls fundamentally affect the economics of selling medical devices in India:

• For price-controlled device categories, your India pricing strategy must account for NPPA caps from the outset
• Revenue per unit in India may be a fraction of what you earn in the US or Europe
• Distribution economics change — traditional distributor margins are compressed, pushing toward direct-to-hospital selling models
• Premium pricing for clinically differentiated devices is possible for non-price-controlled categories, but even for these, there is political risk that NPPA could extend controls at any time

Practical tip: Before entering the Indian market with any implantable device, check whether NPPA price controls apply to your device category. If they do, model your business case against the controlled ceiling price — not your global list price. For devices not currently under price control, build scenario plans for what happens if NPPA extends controls to your category. The Indian government has shown a consistent pattern of expanding device price controls, particularly for high-value implants where there is a perception of price gouging.

Quality Standards and Compliance

ISO 13485 Compliance

ISO 13485 is the cornerstone QMS standard for medical devices in India, as it is globally. Under MDR 2017:

• Class A: ISO 13485 certification is recommended but not mandatory. A self-declaration of quality practices may suffice.
• Class B, C, D: ISO 13485 certification is mandatory. The certificate must be issued by an accreditation body recognized under the IAF MLA or by an Indian Notified Body accredited by NABCB.

Indian Standards (IS) Compliance

In addition to international standards (ISO, IEC), certain medical devices must comply with Indian Standards published by BIS. These may be adopted international standards (e.g., IS/ISO 10993, IS/IEC 60601-1) or India-specific standards. Where an Indian Standard exists for a device category, CDSCO may require a declaration of conformity to that standard.

Good Manufacturing Practice (GMP)

For domestic manufacturers, CDSCO and State Licensing Authorities conduct GMP inspections of manufacturing facilities. The GMP requirements are based on Schedule 5 of the MDR 2017 and are aligned with ISO 13485 principles.

For foreign manufacturers, CDSCO accepts the following as evidence of GMP compliance:

• ISO 13485 certificate from a recognized certification body
• Manufacturing license or facility registration from the home country regulatory authority (e.g., FDA establishment registration)
• GMP certificate from the home country authority
• MDSAP certificate (increasingly accepted)

Sterilization Requirements

Sterilized devices must comply with the applicable sterilization standard (ISO 11135, ISO 11137, ISO 17665, ISO 14937, etc.). For devices sterilized with ethylene oxide (EO), India has adopted limits on EO residuals aligned with ISO 10993-7. CDSCO may request sterilization validation reports as part of the registration dossier for Class C and D sterile devices.

Special Device Categories and Exemptions

Custom-Made Devices

Under Chapters IV and V of MDR 2017, custom-made medical devices — those designed for individual patients based on a practitioner's prescription — are exempt from standard manufacturing and import licensing requirements. However, manufacturers of custom-made devices must still maintain QMS compliance and are subject to post-market obligations. This exemption is narrowly interpreted: the device must be genuinely custom-designed for a specific patient based on specific clinical measurements or requirements, not simply offered in multiple sizes or configurations.

Electronic Instructions for Use (e-IFU)

CDSCO permits electronic Instructions for Use (e-IFU) as an alternative to paper IFUs, provided:

• The e-IFU is identical in content to the paper version
• The e-IFU is accessible at the point of use (this typically means QR code or URL access from the device packaging)
• Paper IFUs must be provided on request at no additional charge

This is relevant for manufacturers seeking to reduce packaging costs and support sustainability goals, but the practical reality is that many Indian healthcare facilities — particularly in Tier 2 and Tier 3 cities — may have limited internet connectivity at the point of use. Consider hybrid approaches.

Non-Sterile Device Exemptions

Non-sterile medical devices are exempt from expiry dating requirements under MDR 2017. However, where shelf life is relevant to device performance (such as adhesive-based products or certain polymer components), manufacturers are still expected to provide use-by dates based on stability data.

Veterinary Medical Devices

Medical devices intended for veterinary use require separate licensing under MDR 2017. If no predicate device exists, a No Objection Certificate (NOC) from the Department of Animal Husbandry is required in addition to CDSCO registration.

Parametric Sterilization Release

For devices sterilized using validated methods (ethylene oxide, gamma radiation, or steam), CDSCO accepts parametric release — meaning that sterility of individual batches can be assured based on process parameters rather than end-product sterility testing, provided the sterilization process is fully validated to the applicable standard (ISO 11135 for EO, ISO 11137 for radiation, ISO 17665 for steam).

India vs. FDA vs. EU MDR: Comparative Framework

Understanding how India's framework compares to the FDA and EU MDR systems helps manufacturers who already have experience with US or European regulation calibrate their India strategy.

Regulatory Aspect	India (CDSCO / MDR 2017)	US (FDA)	EU (MDR 2017/745)
Regulatory authority	CDSCO / DCGI	FDA / CDRH	Notified Bodies + Competent Authorities
Classification system	4 classes (A, B, C, D)	3 classes (I, II, III)	4 classes (I, IIa, IIb, III)
Classification basis	GHTF/IMDRF rules	Device type + intended use + risk	Annex VIII rules (22 rules)
Pre-market pathway	Registration + Import License	510(k), De Novo, PMA	CE marking via conformity assessment
QMS standard	ISO 13485	21 CFR 820 (QMSR/ISO 13485 as of 2026)	ISO 13485 (harmonized standard)
Clinical evidence	Required for Class C/D; Indian population data may be needed	Required for PMA; often for 510(k)	Required for all classes; PMCF for implants/Class III
Local representative	Authorized Indian Agent (mandatory)	US Agent (for foreign establishments)	EU Authorized Representative (mandatory for non-EU manufacturers)
UDI requirement	Phased rollout (2025-2026+)	Fully implemented	Phased rollout (ongoing)
Post-market surveillance	Adverse event reporting + PSUR	MDR (Medical Device Reporting) + 522 studies	PMS plan + PMCF + PSUR/PMSR
Government fees	Very low (USD 30-600)	Moderate to high (USD 6,500-580,000+)	Notified Body fees (variable, typically EUR 10,000-200,000+)
Total registration cost	USD 11,000-75,000+ (excluding clinical)	USD 50,000-1,000,000+ (pathway dependent)	EUR 30,000-500,000+ (class dependent)
Typical timeline	3-24 months (class dependent)	3-18 months (pathway dependent)	6-18 months (class dependent)
Price controls	Yes (NPPA for select device categories)	No (market-based pricing)	No (varies by member state for reimbursement)
Local manufacturing incentives	Yes (PLI scheme, Medical Device Parks)	Some (e.g., CHIPS Act for semiconductors)	No unified EU scheme
Labeling language	English + Hindi (recommended); English mandatory	English	Language of each member state

Key Differences for Manufacturers to Note

Leveraging existing regulatory work: If you already have FDA clearance/approval or EU CE marking, you have a significant head start in India. CDSCO accepts international clinical data, recognizes ISO 13485 certificates from IAF MLA-accredited bodies, and requires a Free Sale Certificate from an existing regulated market. Your existing technical dossier can be adapted (not simply copied) for Indian requirements.

What India adds beyond FDA/EU:

• Mandatory Authorized Indian Agent appointment
• Import license as a separate step after registration
• Potential requirement for Indian population clinical data
• BIS certification for certain device categories (on top of CDSCO registration)
• NPPA price controls for select device categories
• Make in India procurement preferences in public tenders

What India does not yet require that FDA/EU do:

• India's post-market surveillance system, while improving, is less mature than the FDA's MDR/MedWatch system or the EU's vigilance system
• EUDAMED-equivalent centralized database is still in development
• India's UDI system is in early rollout, behind both FDA and EU
• India does not yet have an equivalent of the EU's Summary of Safety and Clinical Performance (SSCP)

Market Size and Opportunity

Market Overview

India's medical device market presents compelling fundamentals:

Metric	Value
Market size (2025)	~USD 14 billion
Projected market size (2030)	~USD 30 billion
CAGR (2025-2030)	~15-17%
Import share	~75-80% of device consumption is imported
Government healthcare spend	~2.1% of GDP (increasing under National Health Policy target of 2.5%)
Hospital bed growth	Adding ~100,000 beds annually through private and public investment
Population	1.44 billion (world's most populous country)
Median age	~28 years (young but aging; chronic disease burden rising rapidly)

High-Opportunity Segments

Segment	Market Driver	Opportunity Level
Cardiovascular devices (stents, pacemakers, heart valves)	High cardiovascular disease burden; growing interventional cardiology infrastructure	Very high (but price-controlled)
Orthopedic implants (joint replacements, trauma fixation)	Aging population, increasing road traffic accidents, rising sports injuries	Very high (but price-controlled for knee/hip)
Diagnostic imaging (CT, MRI, ultrasound, X-ray)	Massive infrastructure gap; government hospital modernization programs	Very high
IVD / diagnostics (POC testing, molecular diagnostics, immunoassay)	Expanding diagnostic access; infectious disease burden; post-COVID laboratory infrastructure growth	Very high
Renal care (dialysis equipment and consumables)	Large dialysis population; government-subsidized dialysis programs (Pradhan Mantri National Dialysis Programme)	High
Ophthalmic devices (IOLs, surgical instruments, diagnostic equipment)	High cataract burden; growing refractive surgery market	High
Digital health / SaMD	Government push for digital health (Ayushman Bharat Digital Mission); smartphone penetration; telemedicine growth	High (evolving regulatory landscape)
Surgical instruments and consumables	Growing surgical volume across all specialties; hospital expansion	High
Respiratory care (ventilators, oxygen concentrators, nebulizers)	Post-COVID investment; chronic respiratory disease burden	Moderate-high

Competitive Landscape

The Indian market has a dual structure:

• High-end segment: Dominated by multinational companies (Medtronic, Abbott, Johnson & Johnson MedTech, Siemens Healthineers, GE Healthcare, Philips, BD, Boston Scientific, Stryker, Smith & Nephew). These companies serve large corporate hospital chains (Apollo, Fortis, Max, Manipal, Narayana Health) and top government hospitals.
• Value segment: Served by Indian domestic manufacturers (Trivitron, Skanray, Opto Circuits, Poly Medicure, Meril Life Sciences, SMT, Sahajanand Medical Technologies) and Chinese manufacturers. This segment focuses on price-competitive products for smaller hospitals, government tenders, and Tier 2-3 city healthcare.

Foreign manufacturers need to decide which segment they are targeting, as the regulatory strategy, pricing, distribution model, and competitive dynamics differ fundamentally between the two.

Tips for Foreign Manufacturers Entering India

Based on the practical realities of the Indian regulatory and commercial environment, here are recommendations for foreign manufacturers.

Regulatory Strategy

1. Start with classification. Confirm your device classification with your AIA before any other regulatory work. If there is ambiguity, request a formal classification determination from CDSCO. This determines everything downstream.

2. Leverage your existing regulatory approvals. Your FDA 510(k)/PMA or EU CE certificate is your strongest asset in the Indian registration process. Build your India dossier from your existing technical file — do not start from scratch.

3. Engage your AIA early and actively. The AIA relationship is not a fire-and-forget transaction. Regular communication, proactive follow-up with CDSCO, and strategic advice on application presentation all matter.

4. Plan for Indian clinical data requirements. For Class C and D devices, determine early whether CDSCO will require Indian clinical data. If so, budget for it in both time and money — this is the longest lead-time item in your India registration.

5. Prepare for BIS certification in parallel. If your device falls under a mandatory BIS standard, start the BIS process simultaneously with the CDSCO registration. Do not wait for one to complete before starting the other — they are independent processes and running them in parallel saves months.

Commercial Strategy

6. Understand pricing constraints. Check whether NPPA price controls apply to your device category. Model your India P&L against controlled prices, not your global price list.

7. Choose the right distribution model. Options include direct sales (for large hospital chains and government tenders), exclusive national distributor, regional distributors, or a hybrid model. Each has different implications for regulatory filings (import license is tied to the importer), pricing, and market coverage.

8. Budget for the long game. India registration timelines are measured in months to years. Distribution relationship building takes additional time. Plan for 18-36 months from the decision to enter India to meaningful commercial revenue.

9. Consider local manufacturing for high-volume products. If your device has significant volume potential and falls in a product category with high import duties or PLI scheme coverage, run the local manufacturing analysis. The economics increasingly favor local production for mid- to high-volume products.

10. Engage with government procurement. A large share of India's device market is driven by government procurement — central government programs, state health missions, and public hospital purchases. Winning government tenders requires competitive pricing, local registration, and often a local manufacturing or assembly presence. Tender compliance requirements can be specific and onerous — experienced AIA or distribution partners can guide you.

Operational Considerations

11. Labeling compliance. Indian labeling requirements differ from US and EU requirements. Ensure your labels include the required information: device name, manufacturer name and address, AIA name and address (for imported devices), batch/lot number, date of manufacture, use-by date (if applicable), single-use designation, sterility indicator, storage conditions, and import license number. Labels must be in English. Hindi is not mandatory but recommended.

12. Customs and logistics. India's customs processes can be slow and unpredictable. Work with a freight forwarder experienced in medical device imports. Ensure all import documentation — import license, registration certificate, certificates of analysis, packaging lists — is complete and correct before shipment. Customs delays cause shelf-life erosion for perishable IVD reagents and time-sensitive products.

13. Intellectual property protection. India is a signatory to major IP treaties (TRIPS, Paris Convention, PCT), and patents are enforceable. However, patent enforcement timelines in Indian courts can be lengthy. File your Indian patent applications early and consider trade secret protection for manufacturing know-how. For devices with design elements, consider design patent protection under the Designs Act.

14. Tax structure. Medical devices in India are subject to Goods and Services Tax (GST). GST rates for medical devices range from 5% (for many implants and life-saving devices) to 12-18% (for other device categories). Customs duties, as noted, add further costs for imported devices. Your AIA or an Indian tax advisor can provide device-specific GST and customs duty classifications.

15. Stay current with regulatory changes. India's medical device regulatory framework is evolving rapidly. Amendments, new notifications, and policy changes are frequent. Subscribe to CDSCO notifications, engage with industry associations (Association of Indian Medical Device Industry — AiMeD; Medical Technology Association of India — MTaI; AdvaMed India Committee), and maintain an active relationship with your AIA to stay ahead of regulatory changes that could affect your registration or commercial operations.

Conclusion

India's medical device regulatory framework has matured substantially since the introduction of MDR 2017. What was once a minimally regulated market is now a comprehensive, risk-based system with mandatory registration, import licensing, quality standards, clinical evidence requirements, and post-market surveillance obligations.

For foreign manufacturers, the Indian market offers exceptional growth potential — but it demands respect for the regulatory process, realistic timeline and budget expectations, and strong local partnerships. The companies that succeed in India are those that invest in understanding the regulatory and commercial environment deeply, choose the right Authorized Indian Agent, and commit to the market for the long term.

The regulatory system will continue to evolve. UDI implementation, digital health regulation, mutual recognition initiatives, and ongoing harmonization with international frameworks will reshape the landscape over the next several years. Manufacturers who establish their Indian regulatory and commercial presence now will be well-positioned to capture the growth that this market promises.